Sign in
WithdrawnPhase 4

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

Key facts

Who runs it
Washington University School of Medicine
Where
Santa Barbara, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 4
Started
13 Sept 2023
Ended
29 May 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard Care
  • Culturally-tailored dietary and behavioral intensive lifestyle intervention
  • Placebo
  • Tirzepatide
Record updated
25 February 2025
Why it stopped
The study was discontinued prematurely for administrative reasons

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Self-reported Hispanic and/or Latino heritage
  • Body Mass Index (BMI) 30-42 kg/m²
  • HbA1c ≤ 6.4%

Who cannot take part

  • Unstable weight (≥4% during the last 2 months prior to study enrollment)
  • Severe cardiovascular disease within the 6 months prior to study enrollment
  • Active substance abuse with alcohol or drugs
  • Metal implants that preclude MRI testing
  • Use of medications that are known to affect the study outcome measures
  • History of chronic or acute pancreatitis
  • Medical conditions that cause obesity
  • History of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder within the last 2 months
  • Uncontrolled hypertension
  • Liver disease
  • Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • History of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
  • Have any other condition not listed in this section (e.g. hypersensitivity or intolerance) that is a contraindication of GLP-1R agonists
  • Previous diagnosis of diabetes or fasting glucose ≥ 126 mg/dl or 2 hr oral glucose tolerance test plasma glucose ≥ 200 mg/dl
  • Calcitonin level of ≥20 ng/L if eGFR ≥60 mL/min/1.73 m2 or ≥35 ng/L if eGFR <60 mL/min/1.73 m2
  • Do not agree to use contraception throughout the study period in male and female participants of reproductive and childbearing age
  • CPAP treatment for obstructive sleep apnea
  • Severe organ system dysfunction
  • Known clinically significant gastric emptying abnormality
  • Thyroid-stimulating hormone (TSH) >1.5X the upper limit of normal
  • Severe anemia
  • Pregnant or breastfeeding
  • Persons who are not able to grant voluntary informed consent
  • Unable or unwilling to follow the study protocol

Where in United States

  • Sansum Diabetes Research InstituteSanta Barbara, United States

About the trial

What the trial wants to find out

The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate, intensive lifestyle intervention (ILI) delivered by community health workers (CHWs) in Latino adults with obesity. Participants will be randomized to 1) standard care (SC, n=25); 2) culturally-tailored dietary and behavioral intensive lifestyle intervention (ILI, n=25) provided by CHWs plus placebo; or 3) ILI plus tirzepatide (ILI-TRZ) for 52 weeks to evaluate the intervention's effect on: i) weight loss; ii) clinical efficacy (change in body fat mass, liver fat, intra-abdominal fat mass and intrahepatic triglyceride content, oral glucose tolerance, glycemic control, insulin sensitivity and b-cell function, plasma lipids, blood pressure, sleep duration, quality and behaviors, physical performance scores); iii) adherence and fidelity to the intervention (adherence to the intervention and barriers to long term adherence, quality-of-life, fidelity of the implementation by CHWs, CHW's and study participants' acceptability and satisfaction with the intervention and eating behaviors. Placebo or tirzepatide will be injected subcutaneously in the abdomen or thigh once a week for 12 months.

The 3 groups in the trial

  • Standard CareExisting treatment, for comparison

    In this arm, participants will receive the standard care intervention from community health workers.

  • Intensive lifestyle intervention plus placeboTreatment being tested

    In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.

    Treatment: Culturally-tailored dietary and behavioral intensive lifestyle intervention and Placebo

  • Intensive lifestyle intervention plus tirzepatideTreatment being tested

    In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention

    Treatment: Culturally-tailored dietary and behavioral intensive lifestyle intervention and Tirzepatide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
Record updated
25 February 2025